Testosterone: long ester
Testosterone Enanthate
An injectable testosterone ester supplied as a 200 mg per mL oil solution for intramuscular use and as a subcutaneous autoinjector, with a half-life of about 4.5 days in the Milligram app (one 2015 study of 10 men measured about 7.2 days), a Schedule III controlled substance in the US and on the WADA Prohibited List.
Testosterone Enanthate after one dose: 50% at ~4.5 days, 25% at 9 days, 12.5% at 13.5 days.
Drawn from the half-life in the app's model, ~4.5 days. The model's figures
- Compound
- Testosterone Enanthate
- Symbol
- TE
- Family
- Testosterone esters
- Parts
- 16
- References
- 17
- Checked
- Last reviewed . Sources are listed below.
How Milligram users log it

22%The 2nd most tracked compound in Milligram: of people who track compounds in Milligram logged Testosterone Enanthate in the last 90 days.
Schedule
Logged doses
Half of people logged between 75 and 250 mg per dose; the median was 137 mg.
Tracked alongside
The share of people logging Testosterone Enanthate who also logged each.
From dose logs in the Milligram app, 90 days to 15 November 2026. Aggregated and anonymous. This describes what people recorded, not what anyone should take.
Overview
Testosterone enanthate, also written test E or test enanthate, is a derivative of testosterone, the primary endogenous androgen.1 Esterification of the 17-beta-hydroxy group increases the duration of action of testosterone, and the US label states that hydrolysis to free testosterone occurs in vivo.1 It is supplied as an oil solution for intramuscular injection, with US labels listing 200 mg per mL in sesame oil, and as the Xyosted autoinjector for subcutaneous use.1,2 The US label for the injection states that it is indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone.1
The half-life of 4.5 days (108 hours) and time to peak of about 48 hours in the figures above are the Milligram app's own, and none of the cited sources states either. The 2015 study measured an apparent half-life of 172.57 hours (about 7.2 days, about 1.6 times longer) and a mean time to peak of 33.30 hours.3 In the United States testosterone enanthate is a Schedule III controlled substance, and testosterone is named among the anabolic androgenic steroids on the WADA Prohibited List.1,4
How it works
In people
After injection the enanthate ester is cleaved to release testosterone, and the Xyosted label states that testosterone enanthate is metabolized to testosterone via ester cleavage of the enanthate group.2 The Xyosted label states that approximately 40% of testosterone in plasma is bound to sex hormone-binding globulin (SHBG) and 2% remains unbound (free), with the rest loosely bound to albumin and other proteins.2 The Xyosted label names estradiol and dihydrotestosterone (DHT) as the major active metabolites of testosterone.2
The US enanthate label states that during exogenous administration of androgens, endogenous testosterone release is inhibited through feedback inhibition of pituitary luteinizing hormone (LH).1 The label adds that at large doses spermatogenesis may also be suppressed through feedback inhibition of pituitary follicle stimulating hormone (FSH).1 In the World Health Organization multicentre study of 271 healthy fertile men given 200 mg of testosterone enanthate weekly by intramuscular injection, 157 men (cumulative rate at 6 months 65%) became azoospermic in three consecutive semen samples.5
Half-life and pharmacokinetics
The Milligram app uses a half-life of about 4.5 days (108 hours), the halveringstijd in Dutch, and a time to peak of about 48 hours for testosterone enanthate, and none of the cited sources states either figure. In a 2015 phase II study, Kaminetsky and colleagues reported an apparent half-life of testosterone of 172.57 hours (SD 34.74) in the reference group given 200 mg of testosterone enanthate by intramuscular injection, and 239.63 hours (SD 59.93) in the 100 mg subcutaneous group.3 The US label for the injection states that testosterone esters in oil injected intramuscularly are absorbed slowly from the lipid phase, so that testosterone enanthate can be given at intervals of two to four weeks.1 The same label cites half-lives of testosterone itself in the literature ranging from 10 to 100 minutes.1 For comparison, the Depo-Testosterone label states that the half-life of testosterone cypionate when injected intramuscularly is approximately eight days.6
| Measure | Figure | Note |
|---|---|---|
| Half-life | ~108 hours (4.5 days) | Milligram app figure; none of the cited sources gives it. A 2015 study measured an apparent half-life of 172.57 hours after 200 mg intramuscular (10 men), about 1.6 times longer, and 239.63 hours after 100 mg subcutaneous.3 |
| Time to peak | ~48 hours | Milligram app figure; none of the cited sources gives it. A 2015 study measured a mean of 33.30 hours (SD 24.52) after 200 mg intramuscular and 35.54 hours (SD 30.40) after 100 mg subcutaneous, and the Xyosted label gives a median of 11.9 hours (range 5.8-168.7) with weekly subcutaneous dosing.3,2 |
| Bioavailability (intramuscular) | ~95% | Milligram app figure; none of the cited sources gives it. The 2015 study found similar total exposure after 100 mg subcutaneous (two doses) and 200 mg intramuscular, and its authors described the bioavailability as similar, without stating a percentage.3 |
| Steady state2,3 | By week 6 with weekly subcutaneous dosing | The Xyosted label states steady state was achieved by Week 6, and the 2015 study states steady state was approached after the third dose. |
| Routes1,2 | Intramuscular, subcutaneous | Oil solution for intramuscular use on US generic labels, and the Xyosted autoinjector for subcutaneous use. |
Level curve between doses
| Source | Regimen | Highest level (Cmax) | Lowest level (Cmin) | Average |
|---|---|---|---|---|
| Kaminetsky and colleagues, 20153 | 200 mg intramuscular, reference group of 10 men | 2261.9 ng/dL (SD 1310.3) | 466.1 ng/dL (SD 199.1) | 1267.5 ng/dL (SD 724.5), over 336 hours |
| Kaminetsky and colleagues, 20153 | 50 mg subcutaneous weekly, 14 men | 622.4 ng/dL (SD 129.5) | 272.9 ng/dL (SD 54.7) | 422.4 ng/dL (SD 123.9), over 168 hours |
| Kaminetsky and colleagues, 20153 | 100 mg subcutaneous weekly, 15 men | 1345.6 ng/dL (SD 435.6) | 568.3 ng/dL (SD 196.4) | 895.5 ng/dL (SD 279.8), over 168 hours |
| Xyosted label, week 122 | 50, 75 or 100 mg subcutaneous weekly, 137 men | 790 ng/dL (SD 215) | 436 ng/dL (SD 109) | 553 ng/dL (SD 127), over 168 hours |
Values from the Milligram app's model.
- Half-life
- ~4.5 days
- Bioavailability
- 95%
- Typical dose
- 150–500 mg/week
- Routes
- IM / SubQ
- Time to peak
- ~48 h
In the 2015 study the authors wrote that in the intramuscular cohort, Cavg and Cmax were higher than normal in the week after dosing.3 Dobs and colleagues reported in 1999 that intramuscular injections of 200 mg every 2 weeks produced supraphysiological levels of testosterone, bioavailable testosterone and estradiol, but not dihydrotestosterone, for several days after each injection.7 In the 2015 study the average dihydrotestosterone after 200 mg intramuscular was 117.1 ng/dL against a reference range of 4 to 57.5, so the two studies differ on dihydrotestosterone.3 The Xyosted label describes the product as producing circulating testosterone concentrations that approximate normal concentrations (300-1100 ng/dL) seen in healthy men.2 Its week 12 table gives average levels from 276 to 1036 ng/dL and lowest levels from 166 to 788 ng/dL across men.2 In the weekly 200 mg World Health Organization regimen, Wu and colleagues attributed effects on skin, muscle, liver, lipid metabolism and haemopoietic function to the relatively high peak levels and fluctuations of plasma testosterone produced by weekly testosterone enanthate.8
The chart below draws the app's one-compartment model for testosterone enanthate, using the app's half-life of 108 hours and time to peak of about 48 hours. It is an illustration, not a measured level, and its half-life is shorter than the 172.57 hours measured in the 2015 study, so its curve falls faster than the measured one.3 The interval choices follow the sources: once weekly in the Xyosted label, 200 mg every 2 weeks in the Dobs trial, and every 2 to 4 weeks in the US enanthate label.2,7,1 Other dose and interval combinations on the chart are arithmetic from the model, not regimens any source tested and not a suggested dose.
Level over 6 weeks
Level, as a share of the peak after one 100 mg dose
As studied: every 7 days2, every 14 days7, every 28 days1. As logged in Milligram: the share of people with three or more logged doses on each schedule (How Milligram users log it).
An illustration from a pharmacokinetic model using a half-life of 108 hours (4.5 days). It is not a measured level or a suggested dose.
What testosterone enanthate products contain per mL
The US label for testosterone enanthate injection, USP states that each mL provides 200 mg of testosterone enanthate in sesame oil with 5 mg of chlorobutanol as a preservative.1
| Product | Manufacturer | Strength | Container |
|---|---|---|---|
| Testosterone enanthate injection, USP1 | Hikma Pharmaceuticals USA Inc. | 200 mg per mL | 5 mL multiple-dose vial, 1,000 mg per 5 mL |
| Testosterone enanthate injection, USP9 | Eugia US LLC | 200 mg per mL | 5 mL multiple-dose vial, 1,000 mg per 5 mL |
| Xyosted autoinjector2 | Antares Pharma, Inc. | 50 mg, 75 mg or 100 mg per 0.5 mL | Single-dose autoinjector, 0.5 mL |
| Depo-Testosterone (testosterone cypionate, for comparison)6 | Pharmacia & Upjohn Company LLC (Pfizer) | 100 mg per mL or 200 mg per mL | 10 mL and 1 mL vials |
The Xyosted label states the volume as 0.5 mL, so dividing its three strengths by 0.5 mL gives 100, 150 and 200 mg per mL.2 The strengths in the table are those printed in the approved labels, and each container label states the strength of that product, for example 1,000 mg per 5 mL (200 mg/mL) on the Hikma vial.1 FDA states that compounded drugs are not FDA-approved and that the agency does not review their safety, effectiveness or quality before they are marketed.10 Compounded and other products are therefore not described by the approved labels above, and the strength of any such product is whatever its own label states.10
The converter below is arithmetic only: it multiplies a volume by a strength in mg per mL, starting from the US label's 200 mg per mL, and the strength printed on a vial's own label is the figure that applies to that vial.1 It converts a volume to a mass for arithmetic only and does not say how much to draw or inject.
Strength converter
US label strength: 200 mg per mL1
Arithmetic only: the amount is the volume times the strength. The vial's own label states its strength.
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Sokol and colleagues, 198211 | Comparative kinetics in eugonadal and hypogonadal men | Not stated | A 200 mg or 100 mg intramuscular injection | In hypogonadal men, calculated mean integrated testosterone and estradiol levels stayed at eugonadal levels through day 11 after 200 mg, and testosterone through day 7 after 100 mg. |
| WHO Task Force, 19905 | Multicentre, ten centres in seven countries | 271 healthy fertile men | 200 mg intramuscular weekly, with a 12-month efficacy phase | 157 of 271 men became azoospermic (65% by 6 months) and only they entered the efficacy phase; 1 pregnancy in 1486 months of that phase (0.8 per 100 person-years, 95% CI 0.02 to 4.5); spermatozoa reappeared in 11 men. |
| Wu and colleagues, 19968 | Secondary analysis of the 1990 cohort | 271 healthy men aged 21 to 45 | 200 mg intramuscular weekly | HDL cholesterol fell 14% to 18% in non-Chinese men, transaminases rose 36% to 51% in Chinese men, and gynecomastia and prostate problems were detected in 24 and 9 men, though no man stopped injections for those reasons; the effects were reversible within 6 months of stopping. |
| Dobs and colleagues, 19997 | Randomised, parallel-group, multicentre, against a testosterone patch | 66 hypogonadal men, 33 per group | 200 mg intramuscular every 2 weeks for 24 weeks | Supraphysiological testosterone for several days after each injection; abnormal hematocrit elevations in 43.8% against 15.4% with the patch. |
| Bhasin and colleagues, 199612 | Randomised, testosterone against placebo, with or without exercise | 43 normal men | 600 mg intramuscular weekly for 10 weeks | Without exercise, triceps area changed +424 against -81 square millimeters and bench-press strength +9 against -1 kg (P < 0.05); neither mood nor behavior was altered in any group. |
| Bhasin and colleagues, 200113 | Randomised, five dose groups, with a GnRH agonist suppressing natural production | 61 healthy men aged 18 to 35 | 25, 50, 125, 300 or 600 mg weekly for 20 weeks | Fat-free mass rose 3.4, 5.2 and 7.9 kg at 125, 300 and 600 mg; sexual function, visual-spatial cognition, mood and PSA did not change significantly at any dose; hemoglobin rose and HDL cholesterol fell as testosterone concentration rose. |
| Coviello and colleagues, 200814 | Secondary analysis of the dose-response study | 60 older men (60 to 75) and 61 young men (19 to 35) | 25, 50, 125, 300 or 600 mg weekly for 20 weeks | Hemoglobin and hematocrit rose in a linear, dose-dependent fashion in both groups, and more in older men. |
| Minnemann and colleagues, 200815 | Open-label, randomised trial designed to test testosterone undecanoate against enanthate | 40 hypogonadal men, 20 on enanthate | 250 mg intramuscular every 3 weeks for 30 weeks | No statistically significant grip strength improvement in either group over 30 weeks; hemoglobin and hematocrit rose significantly in both without exceeding the upper limit of normal; total, LDL and HDL cholesterol and triglycerides fell over the first 30 weeks, and PSA rose slightly within the normal range. |
| Kaminetsky and colleagues, 20153 | Phase II, open-label, three arms | 39 men with hypogonadism | 50 or 100 mg subcutaneous weekly, with 200 mg intramuscular as reference | Mean steady-state testosterone at week 6 was 422.4 and 895.5 ng/dL in the 50 and 100 mg arms. |
| Kaminetsky and colleagues, 201916 | Open-label, single-arm, 52 weeks | 150 men with hypogonadism | 75 mg subcutaneous weekly, adjusted to 50 or 100 mg | 92.7% had an average testosterone of 300 to 1,100 ng/dL at week 12; the most frequent adverse events (increased hematocrit, hypertension, increased PSA) led to discontinuation in 30 of 150 men; no study drug related serious adverse events. |
Sources in this part
- 2Antares Pharma, 2025
- 3Kaminetsky et al., 2015
- 5World Health Organization Task Force on Methods for the Regulation of Male Fertility, 1990
- 7Dobs et al., 1999
- 8Wu et al., 1996
- 11Sokol et al., 1982
- 12Bhasin et al., 1996
- 13Bhasin et al., 2001
- 14Coviello et al., 2008
- 15Minnemann et al., 2008
- 16Kaminetsky et al., 2019
The studies divide into weekly 200 mg dosing in healthy men for contraception, replacement in men with hypogonadism, and graded doses up to 600 mg weekly in healthy men.5,7,13 Several results were null or mixed: neither mood nor behavior changed in any group in the 1996 trial, sexual function, visual-spatial cognition, mood and PSA did not change significantly at any dose in the 2001 trial, and the Minnemann trial found no statistically significant grip strength improvement over its first 30 weeks.12,13,15 Harms in these trials included dose-dependent rises in hemoglobin and hematocrit, a fall in HDL cholesterol in non-Chinese men, and abnormal hematocrit elevations in 43.8% of men on 200 mg every 2 weeks.14,8,7
Deeper analysis: the 2015 subcutaneous pharmacokinetic study
Kaminetsky, Jaffe and Swerdloff published the study in Sexual Medicine in 2015, with the first author at Manhattan Medical Research in New York.3 It was an open-label, parallel-group, dose-finding phase II study, and of 86 men screened between August 28 and November 1, 2013, 39 were dosed.3 The intramuscular group had a mean Cmax of 2261.9 ng/dL (SD 1310.3) and a mean Cmin of 466.1 ng/dL (SD 199.1).3 For the 50 mg group a half-life could not be estimated, which the authors attributed to rising testosterone levels at later time points.3 On limitations the authors wrote that "Randomization of all three treatment arms, including the IM group, would have been a more conventional design" and that the intramuscular arm was included to provide reference data "and not for formal statistic comparison".3 The paper states "This work was supported by Antares Pharma, Inc.", and its disclosures list one author as an Antares Pharma employee, one as a paid consultant to Antares Pharma, and the first author as an investigator for Antares Pharma among other companies.3
Deeper analysis: the 52-week Xyosted registration study
Kaminetsky, McCullough, Hwang, Jaffe, Wang and Swerdloff reported a 52-week registration study in The Journal of Urology in 2019, describing it as open label, single arm and dose blinded.16 The Xyosted label describes a 52-week, open-label study (NCT02159469) in 150 adult males with hypogonadism whose primary endpoint was the percentage of patients with a time-averaged total testosterone over the 7-day dosing interval within the normal range (300 to 1100 ng/dL) at Week 12.2 The paper reports that 92.7% of patients met the primary end point, with a mean of 553.3 (SD 127.29) ng/dL, while the label reports 135 (90%) of the 150 men.16,2 No funding statement or author disclosure is reported for this study in the sources cited here, and the Xyosted label names Antares Pharma, Inc. as the maker of the product.2
Doses reported in studies and on labels
| Source | Dose | Frequency | Length |
|---|---|---|---|
| US label (Hikma), male hypogonadism replacement1 | 50 to 400 mg | Every 2 to 4 weeks | Not stated |
| Xyosted label2 | Starting dose 75 mg; the label changes it by 25 mg according to a trough blood level (decrease at 650 ng/dL or above, increase below 350 ng/dL) | Once weekly, subcutaneous | Not stated |
| Sokol and colleagues, 198211 | 100 mg or 200 mg | Single injection | Not stated |
| WHO Task Force, 19905 | 200 mg | Weekly, intramuscular | 12-month efficacy phase |
| Dobs and colleagues, 19997 | 200 mg | Every 2 weeks, intramuscular | 24 weeks |
| Minnemann and colleagues, 200815 | 250 mg | Every 3 weeks, intramuscular | 30 weeks |
| Bhasin and colleagues, 199612 | 600 mg | Weekly, intramuscular | 10 weeks |
| Bhasin and colleagues, 200113 | 25, 50, 125, 300 or 600 mg | Weekly | 20 weeks |
| Kaminetsky and colleagues, 20153 | 50 or 100 mg subcutaneous, with 200 mg intramuscular reference | Weekly subcutaneous | 6 weeks (subcutaneous arms) |
| Kaminetsky and colleagues, 201916 | 75 mg, adjusted to 50 or 100 mg | Weekly subcutaneous | 52 weeks |
Sources in this part
- 1Hikma Pharmaceuticals USA Inc, 2026
- 2Antares Pharma, 2025
- 3Kaminetsky et al., 2015
- 5World Health Organization Task Force on Methods for the Regulation of Male Fertility, 1990
- 7Dobs et al., 1999
- 11Sokol et al., 1982
- 12Bhasin et al., 1996
- 13Bhasin et al., 2001
- 15Minnemann et al., 2008
- 16Kaminetsky et al., 2019
The US label states: "In general, total doses above 400 mg per month are not required because of the prolonged action of the preparation".1 It also states: "Injections more frequently than every two weeks are rarely indicated".1 Both statements sit in a section that says dosage and duration of therapy depend on age, sex, diagnosis, response to treatment and appearance of adverse effects.1
Side effects reported
Sources in this part
Rates from the Xyosted trials
In the Xyosted label's one-year study of 150 men, adverse reactions reported by more than 5% were hematocrit increased in 21 (14.0%), hypertension in 19 (12.7%), PSA increased in 18 (12.0%), injection site bruising in 10 (6.7%) and headache in 8 (5.3%).2 Across the two studies of 283 men, hematocrit rose to 55% or more in 12 men (4.2%), and polycythemia was reported as a medically significant adverse event in 1.8%.2 Ambulatory blood pressure monitoring in 62 men with acceptable recordings showed mean changes from baseline to week 12 of +3.9 mm Hg systolic (95% CI 1.4-6.4) and +1.5 mm Hg diastolic (95% CI 0.4-2.6).2 The Xyosted label's boxed warning on blood pressure increases was removed in March 2025, and blood pressure increases remain listed under Warnings and Precautions.2 Depression requiring discontinuation was reported in 2 of 283 men and suicide attempts in 2 more, 1.4% in total, and PSA increases led to discontinuation in 4.6%.2
Adverse reactions listed on the US label
The US enanthate label lists gynecomastia, excessive frequency and duration of penile erections, oligospermia at high dosages, hirsutism, male pattern baldness, acne, myocardial infarction, stroke, polycythemia, increased serum cholesterol and venous thromboembolism among its adverse reactions.1 It states that prolonged use of high doses of androgens has been associated with peliosis hepatis and hepatic neoplasms including hepatocellular carcinoma, and that peliosis hepatis can be a life-threatening or fatal complication.1 It also notes rare post-marketing reports of transient reactions with urge to cough, coughing fits and respiratory distress immediately after injection of an oil-based depot preparation.1 The label states that long term clinical safety trials have not been conducted to assess the cardiovascular outcomes of testosterone replacement therapy in men, that studies to date have been inconclusive for determining the risk of major adverse cardiovascular events, and that some studies, but not all, have reported an increased risk.1 TRAVERSE, a trial of topical testosterone gel rather than injected enanthate, in 5198 hypogonadal men aged 45 to 80 years with a history of cardiovascular disease or several risk factors, reported major adverse cardiovascular events in 7.0% on gel and 7.3% on placebo (hazard ratio 0.96, 95% CI 0.78 to 1.17).2 The label also reports a numerically higher incidence of venous thromboembolism on gel (1.7% against 1.2%) and, more often on gel than on placebo, nonfatal arrhythmias needing intervention (5.2% against 3.3%), atrial fibrillation (3.5% against 2.4%), acute kidney injury (2.3% against 1.5%) and bone fracture (3.5% against 2.5%).2
Reports from abuse of anabolic steroids
The label lists serious adverse reactions reported in individuals who abuse anabolic androgenic steroids, including cardiac arrest, myocardial infarction, hypertrophic cardiomyopathy, congestive heart failure, cerebrovascular accident, hepatotoxicity and serious psychiatric manifestations.1
Bloodwork and markers
Total testosterone: the Xyosted label measures the trough seven days after the most recent dose and states that a trough between 350 ng/dL and 650 ng/dL generally provides testosterone exposures in the normal range during the entire dosing interval.2 This trough range is the Xyosted label's target for weekly subcutaneous dosing, and the sources cited here give no trough target for other regimens.2 Both labels state that serum testosterone is measured in the morning on at least two separate days before the diagnosis of hypogonadism is confirmed, and they add that testosterone levels may be in the normal or subnormal range in men abusing synthetic testosterone derivatives.1,2
Free testosterone: the Xyosted label states that 2% of testosterone in plasma remains unbound (free) and that circulating testosterone is primarily bound in serum to sex hormone-binding globulin and albumin.2
Estradiol: the Xyosted label names estradiol as a major active metabolite, and in the 2015 study mean estradiol over 168 hours was 48.3 pg/mL on 100 mg subcutaneous and 50.0 pg/mL on 200 mg intramuscular.2,3 Dobs and colleagues reported supraphysiological estradiol for several days after each 200 mg intramuscular injection.7
Hematocrit: the Xyosted label states to evaluate hematocrit approximately every 3 months and to check that it is not elevated before starting, and the US enanthate label states that hemoglobin and hematocrit are checked periodically for polycythemia in patients receiving high doses of androgens.2,1 The label explains that an increase in red blood cell mass may increase the risk of thromboembolic events, and Coviello and colleagues found hematocrit rising in a dose-dependent way in healthy young and older men.2,14
Lipids: the Xyosted label states that changes in the serum lipid profile may require dose adjustment of lipid lowering drugs or discontinuation of testosterone therapy and that the lipid profile is monitored periodically.2
PSA: the Xyosted label states that patients treated with androgens may be at an increased risk for prostate cancer and lists increased PSA in 12.0% of the one-year study.2 In the 2001 dose-response trial, PSA levels did not change significantly at any dose over 20 weeks.13
Regulatory and anti-doping status
The US enanthate label states that testosterone enanthate contains testosterone, a Schedule III controlled substance in the Controlled Substances Act.1 Under 21 CFR 1308.13, Schedule III includes anabolic steroids, and paragraph (f) lists testosterone, with the schedule covering the listed substances including their salts, esters and ethers.17 The Xyosted label gives initial US approval as 1953.2
The US enanthate label lists primary hypogonadism and hypogonadotropic hypogonadism in males, delayed puberty in carefully selected males, and secondary use in women with advancing inoperable metastatic mammary cancer who are one to five years postmenopausal.1 The US enanthate label states that safety and efficacy in men with age-related hypogonadism have not been established, and the Xyosted label states the same, adding males less than 18 years old.1,2
The WADA Prohibited List 2026, in effect from 1 January 2026, lists testosterone among the anabolic androgenic steroids in S1.1, which are prohibited at all times, in and out of competition.4 The list states that all prohibited substances in class S1 are non-Specified Substances and notes that some may be found in medications used for the treatment of male hypogonadism.4
Storage and handling
Sources in this part
The US enanthate label states that the injection is stored at 20 to 25 degrees Celsius (68 to 77 degrees Fahrenheit), at USP controlled room temperature.1 The same label states that warming and rotating the vial between the palms of the hands will redissolve any crystals that may have formed during storage at low temperatures.1 The Xyosted label states not to refrigerate or freeze, to store at controlled room temperature of 20°C to 25°C with excursions permitted to 15°C to 30°C, and to protect from light by keeping the autoinjector in its carton until use.2
What is not known
Half-life figures differ by study and measurement: the Milligram app uses 108 hours, which none of the cited sources states, the 2015 reference group of 10 men gave an apparent half-life of 172.57 hours, and the US label cites 10 to 100 minutes for testosterone itself.3,1 The 2015 study's intramuscular group was not randomised and, in the authors' words, was not intended for formal statistical comparison.3 The sources listed here report weekly, every 2 week and 2 to 4 week schedules, and none of them reports serum levels for injections given more often than once a week. The US label states that long term clinical safety trials of testosterone replacement therapy in men have not been conducted to assess cardiovascular outcomes, and the large outcome trial the Xyosted label describes, TRAVERSE, tested topical gel and not injected enanthate.1,2 The graded-dose trials ran 10 and 20 weeks, and the label notes that safety and efficacy in men with age-related hypogonadism have not been established.12,13,1
Frequently asked questions
What is testosterone enanthate?
Testosterone enanthate, also written test E, is a derivative of testosterone, the primary endogenous androgen, supplied as an oil solution for intramuscular injection and as a subcutaneous autoinjector. The US label for the injection states that it is indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone.
What is the half-life of testosterone enanthate?
The Milligram app uses a half-life of about 4.5 days (108 hours), which none of the cited sources states. In a 2015 phase II study by Kaminetsky and colleagues, the apparent half-life of testosterone after 200 mg of intramuscular testosterone enanthate averaged 172.57 hours (SD 34.74), about 7.2 days, in the reference group of 10 men. The US enanthate label states that testosterone enanthate can be given at intervals of two to four weeks and cites 10 to 100 minutes as the range of half-lives reported for testosterone itself.
How long does testosterone enanthate stay in the body?
In hypogonadal men, calculated mean integrated testosterone and estradiol levels stayed at eugonadal levels through day 11 after a 200 mg intramuscular injection in the 1982 study by Sokol and colleagues, and the record does not give the number of men. In the 2015 study the lowest testosterone level over a 336-hour interval on 200 mg intramuscular testosterone enanthate averaged 466.1 ng/dL (SD 199.1) in 10 men. The US label states that testosterone enanthate can be given at intervals of two to four weeks.
How long until testosterone enanthate peaks?
The Milligram app uses a time to peak of about 48 hours, which none of the cited sources states. In the 2015 study the mean time to peak testosterone after 200 mg intramuscular was 33.30 hours (SD 24.52). The Xyosted label gives a median of 11.9 hours (range 5.8-168.7 hours) with weekly subcutaneous injection.
How much testosterone enanthate is in 1 mL?
US-labelled testosterone enanthate injection contains 200 mg of testosterone enanthate in each mL, according to the Hikma and Eugia labels. Xyosted is supplied as 50 mg, 75 mg or 100 mg in 0.5 mL, which works out to 100, 150 or 200 mg per mL by division, and the label prints only the per 0.5 mL strengths. Compounded and other products are not described by these labels, and the strength of any such product is whatever its own label states.
What does a testosterone enanthate half-life chart look like?
After 200 mg intramuscular in the 2015 study, the mean peak was 2261.9 ng/dL, the mean time to peak was 33.30 hours and the mean lowest level was 466.1 ng/dL over 336 hours. The table above shows the measured peak and lowest levels, while the adjustable chart is the app's one-compartment model (half-life 108 hours, time to peak 48 hours), so it does not reproduce the measured curve (mean time to peak 33.30 hours, apparent half-life 172.57 hours). The half-life of every compound in the app is charted at milligramapp.com/compounds/.
What is the difference between testosterone enanthate and cypionate?
Both the US enanthate label and the Depo-Testosterone label state a replacement dose of 50 to 400 mg every 2 to 4 weeks. The Depo-Testosterone label states a half-life for cypionate of approximately eight days, the enanthate label gives no half-life for the ester, and a 2015 study measured an apparent testosterone half-life of 172.57 hours (about 7.2 days) after 200 mg intramuscular enanthate in 10 men. US enanthate labels list 200 mg per mL, while Depo-Testosterone lists 100 mg per mL and 200 mg per mL.
Is testosterone enanthate controlled or banned in sport?
Testosterone enanthate is a Schedule III controlled substance in the United States, according to the US label. The WADA Prohibited List 2026 names testosterone among anabolic androgenic steroids prohibited at all times, in and out of competition.
What side effects are reported with testosterone enanthate?
In the Xyosted one-year study of 150 men, hematocrit increased in 14.0%, hypertension was reported in 12.7% and PSA increased in 12.0%. In a separate 24-week trial of 66 hypogonadal men, abnormal hematocrit elevations occurred in 43.8% on 200 mg intramuscular every 2 weeks against 15.4% on a testosterone patch, and the two studies report different measures, so the figures are not comparable. The side effects section above lists more.
What doses of testosterone enanthate have been reported?
The US label states a suggested dosage of 50 to 400 mg every 2 to 4 weeks for replacement in male hypogonadism, and adds that dosage and duration depend on age, sex, diagnosis, response to treatment and adverse effects. The Xyosted label states a starting dose of 75 mg subcutaneously once a week, adjusted by a blood level. Trials have used 25 to 600 mg a week, 200 mg every 2 weeks and 250 mg every 3 weeks.
Guides, tools and comparisons
- Testosterone enanthate dosageA guide that answers a question on this compound.
- Calculator for Testosterone EnanthateA calculator set up for this compound.
- Testosterone cypionate vs enanthateA side-by-side with another compound.
- Previous in Testosterone esters: Testosterone CypionateThe compound before this one in the class.
- Next in Testosterone esters: Testosterone IsocaproateThe compound after this one in the class.
References
- Hikma Pharmaceuticals USA Inc. Testosterone Enanthate Injection, USP, 200 mg/mL. DailyMed label, effective 2026. DailyMed label
- Antares Pharma, Inc. XYOSTED (testosterone enanthate) injection, for subcutaneous use. DailyMed label, effective 2025 (boxed warning removed 03/2025). DailyMed label
- Kaminetsky J, Jaffe JS, Swerdloff RS. Pharmacokinetic profile of subcutaneous testosterone enanthate delivered via a novel, prefilled single-use autoinjector: a phase II study. Sex Med 2015. PMID 26797061
- World Anti-Doping Agency. Prohibited List 2026, in effect from 1 January 2026. WADA list
- World Health Organization Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet 1990. PMID 1977002
- Pharmacia & Upjohn Company LLC (Pfizer). DEPO-Testosterone (testosterone cypionate) injection. DailyMed label, effective 2026. DailyMed label
- Dobs AS, et al. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 1999. PMID 10522982
- Wu FC, et al. Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. Fertil Steril 1996. PMID 8774299
- Eugia US LLC. Testosterone Enanthate Injection, USP, 200 mg/mL. DailyMed label, effective 2026. DailyMed label
- US Food and Drug Administration. Understanding the risks of compounded drugs. FDA web page. FDA page
- Sokol RZ, et al. Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertil Steril 1982. PMID 6800853
- Bhasin S, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996. PMID 8637535
- Bhasin S, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 2001. PMID 11701431
- Coviello AD, et al. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab 2008. PMID 18160461
- Minnemann T, et al. Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism. J Endocrinol Invest 2008. PMID 18852533
- Kaminetsky JC, et al. A 52-week study of dose adjusted subcutaneous testosterone enanthate in oil self-administered via disposable auto-injector. J Urol 2019. PMID 30296416
- US Drug Enforcement Administration. 21 CFR 1308.13, Schedule III. Electronic Code of Federal Regulations. eCFR